Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB-02) in Patients With Advanced Solid Tumors.

CPT Pharmacometrics Syst Pharmacol · 2025 · PMC12072225 · PMID 40067130

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a negative trendno p-value reported

Exposure metrics at C2D1 for the patients included in the ER analysis of safety ( n = 35) indicated that there was a negative trend between AUC or C max and the incidence of anaphylaxis (Figure 6a,b ), this trend was not a statistically significant relationship ( p > 0.05).

also in 4,201 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.